H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics (LSTA – Research Report) today and set a price target of $15.00.
Joseph Pantginis’s Buy rating for Lisata Therapeutics is based on a multitude of promising developments that the company has made in its clinical trials. First and foremost, Lisata has begun the Phase 2a BOLSTER clinical trial, where it has started dosing patients with its leading product, LSTA1, to treat advanced solid tumors. This trial is expected to evaluate multiple tumor cohorts. The company has also recently commenced dosing the first patient in the head and neck squamous cell carcinoma cohort. The diversity of clinical trials that LSTA1 is involved in is particularly encouraging.
Furthermore, the LSTA1 is also under evaluation in several other studies. One of them is the ASCEND Phase 2b study, which is investigating LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma. The trial has already achieved over 70% of its enrollment target. Another is the CENDIFOX Phase 1b/2a trial, which focuses on LSTA1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon, and appendiceal cancers. This trial is making steady progress, with enrollment completion expected by the end of 2023. Additionally, there are other ongoing trials and planned studies involving LSTA1, adding to the anticipation of future updates from Lisata Therapeutics. All these factors contribute to Pantginis’s positive outlook for the company.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Lisata Therapeutics (LSTA) Company Description:
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More on LSTA:
- Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
- Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
- Lisata Therapeutics announces EMA granted LSTA1 orphan drug designation
- Lisata Therapeutics Announces Participation in Upcoming Conferences in October
- Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
